Purple Biotech Reports Q3 2024 Financial Results
Ticker: PPBT · Form: 6-K · Filed: Nov 15, 2024 · CIK: 1614744
Sentiment: neutral
Topics: financial-results, 6-K, biotech
TL;DR
Purple Biotech dropped its Q3 2024 earnings report on Nov 15th.
AI Summary
Purple Biotech Ltd. announced its third quarter 2024 financial results on November 15, 2024. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with an update on Purple Biotech's financial performance for the third quarter of 2024, which is crucial for assessing the company's operational health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing with no new material events or significant financial changes disclosed.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the report
- Kitov Pharma Ltd. (company) — Former name of Purple Biotech Ltd.
- November 15, 2024 (date) — Date of press release and filing
- Rehovot, Israel (location) — Company's principal executive offices
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report Purple Biotech Ltd.'s third quarter 2024 financial results via an attached press release.
When were the third quarter 2024 financial results announced?
The third quarter 2024 financial results were announced on November 15, 2024.
What was Purple Biotech Ltd. formerly known as?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Where are Purple Biotech Ltd.'s principal executive offices located?
Purple Biotech Ltd.'s principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Which SEC form is Purple Biotech Ltd. required to file annually as a foreign private issuer?
As a foreign private issuer, Purple Biotech Ltd. is required to file its annual reports under cover of Form 20-F.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-11-15 07:02:02
Filing Documents
- ea0221358-6k_purple.htm (6-K) — 14KB
- ea022135801ex99-1_purple.htm (EX-99.1) — 143KB
- 0001213900-24-098732.txt ( ) — 158KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. November 15, 2024 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2